Last reviewed 2026-04-22 · How we verify

Emtricitabine / Tenofovir Disoproxil Pill

Emtricitabine / Tenofovir Disoproxil Pill is a Nucleoside/nucleotide reverse transcriptase inhibitor combination Small molecule drug developed by Fundacion IDEAA. It is currently FDA-approved for HIV-1 infection treatment (as part of combination antiretroviral therapy), HIV-1 pre-exposure prophylaxis (PrEP) in at-risk individuals. Also known as: truvada, dolutegravir.

Emtricitabine and tenofovir disoproxil are nucleoside/nucleotide reverse transcriptase inhibitors that block HIV replication by inhibiting the enzyme responsible for converting viral RNA into DNA.

Emtricitabine/Tenofovir Disoproxil (FTC/TDF) is a fixed-dose combination antiretroviral marketed by Fundacion IDEAA for HIV-1 treatment and PrEP. This dual nucleoside reverse transcriptase inhibitor (NRTI) combination represents a well-established, first-generation backbone therapy with extensive clinical validation across 58 trials and 188 publications. The drug addresses both treatment-naive and prevention populations, with demonstrated efficacy in adults and pediatric patients meeting weight thresholds. As a mature, generic-available therapy, it maintains significant commercial relevance in resource-limited settings and remains foundational in modern antiretroviral regimens despite newer alternatives.

At a glance

Mechanism of action

Emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) are antiretroviral agents that work synergistically to suppress HIV-1 replication. Both drugs inhibit reverse transcriptase, the viral enzyme essential for HIV to integrate into host cell DNA. This combination is commonly used as part of highly active antiretroviral therapy (HAART) regimens and is also approved for pre-exposure prophylaxis (PrEP) to prevent HIV acquisition in at-risk individuals.

Approved indications

• HIV-1 infection treatment (as part of combination antiretroviral therapy)
• HIV-1 pre-exposure prophylaxis (PrEP) in at-risk individuals

Common side effects

• Nausea
• Diarrhea
• Headache
• Fatigue
• Renal impairment (tenofovir-related)
• Bone density loss (tenofovir-related)
• Lactic acidosis (rare)

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Emtricitabine / Tenofovir Disoproxil Pill CI brief — competitive landscape report
• Emtricitabine / Tenofovir Disoproxil Pill updates RSS · CI watch RSS
• Fundacion IDEAA portfolio CI

Frequently asked questions about Emtricitabine / Tenofovir Disoproxil Pill

Related

• Drug class: All Nucleoside/nucleotide reverse transcriptase inhibitor combination drugs
• Target: All drugs targeting HIV-1 reverse transcriptase
• Manufacturer: Fundacion IDEAA — full pipeline
• Therapeutic area: All drugs in Infectious Disease / Virology
• Indication: Drugs for HIV-1 infection treatment (as part of combination antiretroviral therapy)
• Indication: Drugs for HIV-1 pre-exposure prophylaxis (PrEP) in at-risk individuals
• Also known as: truvada, dolutegravir
• Compare: Emtricitabine / Tenofovir Disoproxil Pill vs similar drugs
• Pricing: Emtricitabine / Tenofovir Disoproxil Pill cost, discount & access